The promise of molecular biology: Efficacy, safety, wallet depletion
Molecular biology is entering its second wave, with effective but expensive treatments. Recombinant human parathyroid hormone (PTH) is a case in point.
J.D. CLOUGH

Recombinant human PTH 1-34 (Forteo): An anabolic drug for osteoporosis
We have an important new drug for osteoporosis. Now who should get it? And who will pay for it?
C. DEAL and J. GIDEON

A 34-year-old man with facial droop and dysarthria
A previously well man develops flulike symptoms and focal neurologic deficits. What is the cause? 
A.A. LATIF, H. JNEID, C.M. ISADA, and G.S. FRANCIS

Managing weight gain as a side effect of antidepressant therapy
Some drugs are more apt to cause weight gain than others; one should inform and work with the patient.
R. DESHMUKH and K. FRANCO

Amiodarone-induced thyrotoxicosis: Diagnostic and therapeutic strategies
It is difficult but important to distinguish the two types of amiodarone-induced thyrotoxicosis.
G.A. CARDENAS, J.M. CABRAL, and C.A. LESLIE

Are we winning or losing the war on cancer?
The news from the cancer front is good and bad.
M. MARKMAN

Using C-reactive protein to assess cardiovascular disease risk
CRP is now a recognized cardiac test. But who should be tested?
M.H. SHISHEHBOR, D.L. BHATT, and E.J. TOPOL

New advances transform the management of women with abnormal Pap tests
We review the new thin-layer slide system, the new HPV test, the 2001 reporting system for Pap tests, and new management guidelines.
X.W. JIN, C. NIELSEN, J. BRAINARD, and B. YEN-LIEBERMAN

In refractory temporal lobe epilepsy, consider surgery sooner
Epilepsy surgery is perhaps the most underused therapy in all of medicine today.
R. LACHHWANI and H. LÜDERS

Classified Advertisements
CME Self-test Online